We strongly encourage providers to treat or refer patients who are at increased risk of severe disease and have developed COVID-19 symptoms as soon as they are eligible for treatment.

BILH COVID-19 Outpatient Treatment Program

Providers should directly prescribe nirmatrelvir with ritonavir (Paxlovid) to a BILH Outpatient Pharmacy or a retail pharmacy with available supply. Use of oral therapy is the preferred option for treatment when no contraindications are present.

For patients who are unable to receive nirmatrelvir with ritonavir (Paxlovid) due to significant medication interactions or other contraindications, other outpatient COVID-19 treatment is also available at:

  • Providers with WebOMR Access: (All three of the following must be completed):
    • Under “Consults” place a WebOMR order for “COVID-19 Ambulatory Treatment Scheduling”
    • In the WebOMR Infusion/Pheresis tab place a “New Infusion Order” for the “Remdesivir” order set
    • Enter a note in WebOMR using the Macro entitled “COVID-19 Amb Treatment (symptomatic patient)” under “{COVID-19 Ambulatory Treatment} (2 entries)”
  • Providers without WebOMR Access:

Note: Lahey Hospital & Medical Center is not providing remdesivir infusion for ambulatory patients at this time.

Providers should also consider referral to the following:

  • State-funded sites across Massachusetts provide oral therapy and monoclonal antibody therapy.
  • Massachusetts DPH in-home treatment program for individuals who qualify. Review eligibility requirements here.
  • Primarily intended for use by uninsured individuals, telehealth is available for individuals 18 or older living in Massachusetts who test positive for COVID-19 and are experiencing symptoms. This telehealth service can determine if nirmatrelvir with ritonavir (Paxlovid) may be an option. If it is, pickup at a pharmacy or free overnight delivery is available. Learn more.

BILH COVID-19 Patient Treatment Guidance (BILH clinicians only, password required)